Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525311 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.
A Phase 1 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT06525311 is a Phase 1 study that has completed, run by Kowa Research Institute. The registered enrollment target is 17 participants.
The verdict
NCT06525311, a Phase 1 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.
Interventions
- DRUG K-808
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2025-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06525311
The ClinicalTrials.gov registry entry for NCT06525311 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which K-808 is the first listed.
NCT06525311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06525311 about?
NCT06525311 is a clinical study titled "A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.". A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.
What is the current status of trial NCT06525311?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2024-10-01. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT06525311?
The interventions under investigation include: K-808 (DRUG).
Who is sponsoring clinical trial NCT06525311?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.